Target intelligence / Profile preview

Zinc transporter protein (None)

Target
None
Molecular classification
Transporter, Ion channel, Cation transport protein
01

Overview

Zinc transporter proteins encompass two major families: the ZnT (SLC30) family and the ZIP (SLC39) family[6][5]. ZnT transporters reduce cytosolic zinc concentrations by exporting zinc out of the cytosol to the extracellular space or into organelles, whereas ZIP transporters increase cytosolic zinc by importing zinc from extracellular or organellar compartments[6][5][3]. There are 10 ZnT proteins and 14 ZIP proteins identified in humans, each with specific tissue expression and subcellular localization[3][5][6]. Their activity is tightly regulated and crucial for zinc-dependent processes including enzymatic catalysis, signaling, and protein folding. Dysregulation or genetic defects in zinc transporters are linked to diseases such as cancer, neurodegeneration, and inflammation[5][4]. Experimental and structural studies have shown that transporter activity is sensitive to intracellular zinc concentrations, and both families have complex regulatory mechanisms at both the transcriptional and post-translational levels[2][3][4][6].

Other names
ZnT proteinsSLC30 family (ZnT1–ZnT10)ZIP proteinsSLC39 family (ZIP1–ZIP14)
02

Mechanism of action

Drugs (such as chelators) would regulate zinc transport by inhibiting uptake/export; other experimental therapies may affect transporter expression or activity

03

Biological functions

Cellular zinc homeostasisMaintenance of cytoplasmic and organellar zinc concentrationsSignal transduction (zinc signaling)Vesicular exocytosis of zincRegulation of protein stability/folding in secretory pathway (e.g., ERp44 interaction)
04

Disease associations

CancerNeurodegenerative diseaseInflammationOther (e.g., growth/developmental disorders due to zinc imbalance)
05

Safety considerations

Perturbation of zinc homeostasis may cause cytotoxicity or apoptosisRisk of disrupting essential zinc-dependent enzymatic and signaling functionsEmbryonic lethality observed with ZnT1 knockout
06

Interacting drugs

No FDA-approved direct drugs targeting zinc transporter proteins, but modulators of zinc homeostasis or chelators can affect their function; no named drugs found in search results
07

Biomarkers

Expression levels of ZIP and ZnT subtypes (e.g., ZIP4 mutations can act as disease biomarkers)Intracellular or plasma zinc levels

Beyond the preview

Go deeper on Zinc transporter protein (None).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zinc transporter protein (None).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call